Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven C Clifford

Showing results (21-30 of 123) with videos related to

Pageof 13
Sort By:
Genes, Chromosomes & Cancer|November 1, 2008
Novel mechanisms of gene disruption at the medulloblastoma isodicentric 17p11 breakpointMartin G McCabe, Koichi Ichimura, Danita M Pearson, et al.
Acta Neuropathologica Communications|June 24, 2025
Robust molecular subgrouping and reference-free aneuploidy detection in medulloblastoma using low-depth whole genome bisulfite sequencingDean Thompson, Jemma Castle, Martin Sill, et al.
Cancers|January 21, 2022
Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB TrialSimon Bailey, Nicolas André, Lorenza Gandola, et al.
Cancer Genetics and Cytogenetics|July 18, 2006
APC and CTNNB1 mutations are rare in sporadic ependymomasOlabisi E Onilude, Meryl E Lusher, Janet C Lindsey, et al.
British Journal of Neurosurgery|December 16, 2011
The importance of biopsy following radiological diagnosis of relapsed medulloblastomaJonathan Fisher, Dipayan Mitra, Lisa Price, et al.
Cancers|March 28, 2024
Correction: Bailey et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. <i>Cancers</i> 2022, <i>14</i>, 374Simon Bailey, Nicolas André, Lorenza Gandola, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2006
Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastomaRichard J Gilbertson, Jaqueline A Langdon, Andrew Hollander, et al.
Cancers|December 10, 2021
SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk MedulloblastomaMartin Mynarek, Till Milde, Laetitia Padovani, et al.
Neuro-Oncology|July 31, 2008
Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2Jennifer A Anderton, Janet C Lindsey, Meryl E Lusher, et al.
Cell Cycle (Georgetown, Tex.)|December 19, 2006
Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosisSteven C Clifford, Meryl E Lusher, Janet C Lindsey, et al.
Pageof 13

Showing results (21-30 of 123) with videos related to

Sort By:
Pageof 13
Genes, Chromosomes & Cancer|November 1, 2008
Novel mechanisms of gene disruption at the medulloblastoma isodicentric 17p11 breakpointMartin G McCabe, Koichi Ichimura, Danita M Pearson, et al.
Acta Neuropathologica Communications|June 24, 2025
Robust molecular subgrouping and reference-free aneuploidy detection in medulloblastoma using low-depth whole genome bisulfite sequencingDean Thompson, Jemma Castle, Martin Sill, et al.
Cancers|January 21, 2022
Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB TrialSimon Bailey, Nicolas André, Lorenza Gandola, et al.
Cancer Genetics and Cytogenetics|July 18, 2006
APC and CTNNB1 mutations are rare in sporadic ependymomasOlabisi E Onilude, Meryl E Lusher, Janet C Lindsey, et al.
British Journal of Neurosurgery|December 16, 2011
The importance of biopsy following radiological diagnosis of relapsed medulloblastomaJonathan Fisher, Dipayan Mitra, Lisa Price, et al.
Cancers|March 28, 2024
Correction: Bailey et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. <i>Cancers</i> 2022, <i>14</i>, 374Simon Bailey, Nicolas André, Lorenza Gandola, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2006
Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastomaRichard J Gilbertson, Jaqueline A Langdon, Andrew Hollander, et al.
Cancers|December 10, 2021
SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk MedulloblastomaMartin Mynarek, Till Milde, Laetitia Padovani, et al.
Neuro-Oncology|July 31, 2008
Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2Jennifer A Anderton, Janet C Lindsey, Meryl E Lusher, et al.
Cell Cycle (Georgetown, Tex.)|December 19, 2006
Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosisSteven C Clifford, Meryl E Lusher, Janet C Lindsey, et al.
Pageof 13